Related Experiment Video
Updated: Feb 27, 2026

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
Published on: June 9, 2018
High phenotypic variability in Gerstmann-Sträussler-Scheinker disease
Jerusa Smid1, Adalberto Studart1, Michele Christine Landemberger2
1Universidade de São Paulo, Faculdade de Medicina, Departamento de Neurologia, São Paulo SP, Brasil.
Gerstmann-Sträussler-Scheinker syndrome (GSS) is a genetic prion disease. The p.Pro102Leu mutation causes varied GSS phenotypes, with codon 129 heterozygosis linked to earlier onset.
Area of Science:
- Neuroscience
- Genetics
- Pathology
Background:
- Gerstmann-Sträussler-Scheinker syndrome (GSS) is a rare, autosomal dominant genetic prion disease.
- The p.Pro102Leu mutation in the PRNP gene is the most common cause of GSS.
- Clinical presentation of GSS is highly variable, posing diagnostic challenges.
Purpose of the Study:
- To characterize the clinical, molecular, and neuropathological features of GSS in two Brazilian kindreds.
- To investigate the influence of PRNP codon 129 polymorphism and apoE genotype on GSS phenotype variability.
- To understand the genetic basis of disease heterogeneity in GSS.
Main Methods:
- Clinical data collection: patient history, age at onset, disease duration, and phenotypic presentation.
- Molecular analysis: PRNP sequencing and analysis of codon 129 polymorphism and apoE genotype.
- Neuropathological examination: assessment of brain tissue for prion protein deposits (PrPSc) and characteristic plaques.
Main Results:
- Seven individuals from two unrelated Brazilian kindreds carrying the p.Pro102Leu mutation were studied.
- Significant variability in age at onset, disease duration, and clinical phenotypes (dementia vs. ataxia) was observed.
- Codon 129 heterozygosis was associated with earlier disease onset, but did not fully explain clinical variability; apoE genotype showed no association.
- Neuropathology confirmed GSS hallmarks, including plaques and PrPSc immunopositivity.
Conclusions:
- The p.Pro102Leu mutation in GSS exhibits marked clinical heterogeneity, even within families.
- PRNP codon 129 heterozygosis may influence GSS onset but does not account for the full spectrum of clinical variability.
- Further research is needed to elucidate other genetic or environmental factors contributing to GSS phenotype diversity.
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic Lingo
Principles of Pharmacogenetics: Types of Genetic Variants
Pleiotropy
Multiple Allele Traits
Pedigree Analysis

